In this prospective study, all the eligible patients will be given Pola-R2 regimen(polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days). An interim evaluation will be performed after 4 cycles, the patients who achieve CR or PR will receive another 4 cycles of Pola-R2.
The patients with stable disease (SD) or progressed disease (PD) will withdraw from the trial and receive salvage regimens.
Age
70–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient volunteered to participate in the study and signed the Informed Consent
Histopathologically confirmed DLBCL and treatment naive(corticosteroids alone is not considered as a line of treatment)
Age≥ 70 years old, and was un-fit or frail according to comprehensive geriatric assessment
Adequate organ function and adequate bone marrow reserve
You may not be if
Coexisting malignancy other than lymphoma
Active HBV infection
Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy